• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » U.K. general public has fundamental misunderstanding of cost and value of medicines

U.K. general public has fundamental misunderstanding of cost and value of medicines

September 3, 2012
CenterWatch Staff

A new survey commissioned by the ABPI, has revealed that the British public misunderstands the cost and value of medicines in the U.K.

The survey, which was conducted by GfK NOP and interviewed 1,000 people, show that many mistakenly believe the NHS spends much more on medicines than it actually does, while there is poor understanding of the huge expense involved in their discovery, development, approval and launch.

The head of the U.K. pharmaceutical industry believes it is vital that the public better understands the facts and fully appreciates their low cost compared to their considerable economic and health benefits.

The survey shows that over a third of respondents (35%) think that 20% or more of the NHS budget is spent on medicines. In reality, the NHS spent just 9.7% of its entire budget on medicines in 2011, down from 12.5% in 1999.

Among the most striking of the figures, the survey shows that over half of people (59%) think that it costs pharmaceutical companies less than $15.8 million to research and develop a medicine. This shows that people have a poor understanding of the huge investment required to bring a medicine to market as it costs on average over $1.5 billion to create a new medicine—a process that typically takes over 12 years.

The survey also found that 77% of patients would like spending on medicines to increase or stay the same compared with 19% that would opt for a decrease. Spending in this area is set to stay flat over the next three years but spending on the newest medicines is set to fall significantly to just 2% of the overall budget for medicines by 2015.

"I am really concerned that people do not understand the cost or value of medicines in this country,” said Stephen Whitehead, chief executive of the ABPI. “To create new treatments in the U.K., the pharmaceutical industry undertakes huge risk and investment and is still able to provide the NHS with amongst the lowest priced medicines in Europe. These medicines are the bedrock of the NHS, and have saved and changed the lives of millions of people. Many diseases which once caused significant suffering, such as HIV, diabetes and heart disease, are now manageable conditions which people can live with until old age, and their treatment becomes cheaper as generics can be used once medicines lose their patent.

Whitehead continued, "What's more, our medicines can save the system money because their effective use can often reduce the need for expensive hospital care and operations. As well providing real value, we also contribute billions annually to the U.K. economy and provide 67,000 jobs. In the coming months we will be doing much to educate people and patients of the facts about medicines—the huge benefits, the low prices and the high cost of development."

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing